On February 10, 2020 Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, reported the pricing of an underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share (Press release, Apricus Biosciences, FEB 10, 2020, View Source [SID1234554135]). In addition, the Company granted the underwriters a 45-day option to purchase up to 999,999 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Raj Mehra, Ph.D., the President, Chief Executive Officer and Chairman of the Board of Directors of Seelos, intends to purchase shares in the offering at the public offering price.
Benchmark Company is acting as sole book-running manager for the offering.
Seelos anticipates the aggregate net proceeds from the offering will be approximately $4.3 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by Seelos, but excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates. This offering is expected to close on or about February 13, 2020, subject to the satisfaction of customary closing conditions.
The securities described above were offered by Seelos pursuant to a registration statement on Form S-1 (File No. 333-236002) previously filed with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC on February 10, 2020. The securities may be offered only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to and describing the offering has been filed with the SEC. Electronic copies of the preliminary prospectus and, when available, copies of the final prospectus relating to the offering may be obtained by visiting the SEC’s website at www.sec.gov or by contacting The Benchmark Company, LLC, Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at [email protected].
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.